CVS Medicare Advantage business takes quality rating hit


CVS sign is shown in Wadsworth Plaza in Philadelphia, Wednesday, Sept. 29, 2021. CVS Health shares tumbled early Friday, Oct. 7, 2022, after the company said a big Medicare Advantage plan took a hit in government quality ratings about a week before a key enrollment window opens for the coverage. (AP Photo/Matt Rourke)

CVS Health shares tumbled early Friday after the company said a big Medicare Advantage plan took a hit in government quality ratings about a week before a key enrollment window opens for the coverage.

The health care giant said that its Aetna National PPO dropped from 4.5 stars to 3.5 in 2023 ratings, which were released Thursday by the Centers for Medicare and Medicaid Services.

Plans are rated on a scale of 1 to 5, with five representing excellent, according to CMS. The ratings are released annually and reflect the experiences of people enrolled in the plan.

The drop means the plan will no longer be eligible for a CMS quality bonus payment. It also could affect enrollment, since some shoppers factor the ratings into their coverage decision.

The Aetna plan covers all 50 states with nearly 2 million people enrolled, which is more than half of Aetna’s total Medicare Advantage enrollment. Aetna is the health insurance division of CVS Health, which also runs a national drugstore chain and manages prescription drug coverage.

CVS Health said the main reason for the rating drop was a scoring system based on survey results from 976 customers, or well under 1% of the plan’s enrollment.

Medicare Advantage plans are privately run versions of the government’s Medicare program for people who are age 65 and older or have certain disabilities. The annual enrollment window for 2023 plans opens Oct. 15 and runs until Dec. 7.

Shares of CVS Health Corp., which is based in Woonsocket, Rhode Island, were down 4.7%, or $4.65, to $93.93 before markets opened Friday.

Should you invest $1,000 in CVS Health right now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Aetna (AET)
0 of 5 stars
$212.70flat0.94%21.57N/A
CVS Health (CVS)
5 of 5 stars
$67.32-0.7%3.95%10.42Moderate Buy$89.44
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Search Headlines: